Diaceutics PLC Purchase and Sale of Shares and PDMR Shareholdings (7228B)
06 June 2023 - 4:00PM
UK Regulatory
TIDMDXRX
RNS Number : 7228B
Diaceutics PLC
06 June 2023
6 June 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Purchase and Sale of Shares and PDMR Shareholdings
Diaceutics PLC , ( AIM: DXRX), a leading technology and
solutions provider to the pharmaceutical industry announces the
following Director and PDMR share dealing.
On 5 June 2023, Nick Roberts, CFO of Diaceutics, purchased
21,742 ordinary shares of GBP0.002 each in the Company ("Ordinary
Shares") at a price of 91.75 pence per Ordinary Share. As a result
of the purchase, Nick's shareholding is 62,576 Ordinary Shares,
representing approximately 0.07% of the Company's issued share
capital.
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Via Alma PR
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Nick Harland
Nick Adams
Kate Hanshaw
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome. We provide the world's
leading pharmaceutical and life science companies with solutions
and technology for the commercialisation of their precision
medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, utilising a global network of affiliate
laboratories to deliver multiple pipelines of real-world healthcare
data insights, advisory services and innovative platform enabled
solutions.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ ------------------------------------------------------------------------------------------
a. Name Nick Roberts
----------------------------------------------
2 Reason for notification
------------------------------------------ ----------------------------------------------
a. Position/Status CFO
------------------------------------------ ----------------------------------------------
b. Initial notification/ Initial
Amendment
----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ ------------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP 0.002 each
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ----------------------------------------------
b. Nature of the Purchase
transaction
------------------------------------------ ----------------------------------------------
c. Price(s) and volume(s) Share purchase:
------------------------------------------ ------------------------------------------
Price(s) Volume(s)
------------------------------------------ --------------------
91.75p 21,742
-------------------- --------------------
d. Date of the transaction 5 June 2023
------------------------------------------ ----------------------------------------------
e. Place of the transaction AIM Market of the London Stock Exchange
------------------------------------------ ----------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFFFLIRRIEIIV
(END) Dow Jones Newswires
June 06, 2023 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024
